Drug Profile
BT 063
Alternative Names: BT-063Latest Information Update: 27 Apr 2022
Price :
$50
*
At a glance
- Originator Biotest
- Developer Biotest AG
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 10 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 25 Apr 2022 Biotest AG has been acquired by Grifols
- 15 Apr 2021 No development reported - Phase-II for Systemic lupus erythematosus in Georgia, Serbia, Belarus, Poland (IV)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus(In volunteers) in Germany (IV, Infusion)